Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

  1. Usmani, S.Z.
  2. Nahi, H.
  3. Legiec, W.
  4. Grosicki, S.
  5. Vorobyev, V.
  6. Spicka, I.
  7. Hungria, V.
  8. Korenkova, S.
  9. Bahlis, N.J.
  10. Flogegard, M.
  11. Bladé, J.
  12. Moreau, P.
  13. Kaiser, M.
  14. Iida, S.
  15. Laubach, J.
  16. Magen, H.
  17. Cavo, M.
  18. Hulin, C.
  19. White, D.
  20. De Stefano, V.
  21. Lantz, K.
  22. O'Rourke, L.
  23. Heuck, C.
  24. Delioukina, M.
  25. Qin, X.
  26. Nnane, I.
  27. Qi, M.
  28. Mateos, M.-V.
  29. Erakutsi egile guztiak +
Aldizkaria:
Haematologica

ISSN: 1592-8721

Argitalpen urtea: 2022

Alea: 107

Zenbakia: 10

Orrialdeak: 2408-2417

Mota: Artikulua

DOI: 10.3324/HAEMATOL.2021.279459 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus